Bristol-Myers Squibb Company - Iza-Bren Demonstrates Clinical Benefit In Five Distinct Tumor Types

Safety Profile For Iza-Bren Was Manageable And No New Safety Signals Were Identified CORR 40.5% For Iza-Bren Vs 20.2% For Chemotherapy; MDOR 6.9 Vs 4.2 Months Iza-Bren Reduces Risk Of Progression Or Death By 59% In Phase 3 Breast Cancer Study